5 Allergy Headlines You Missed in August 2025

In this month’s allergy review, several developments mark progress in the field. The US Food and Drug Administration (FDA) approved donidalorsen (DAWNZERA), the first RNA-targeted prophylaxis for hereditary angioedema (HAE). Additionally, the American Society for Dermatologic Surgery issued an advisory recommending cephalexin as the preferred antibiotic for patients who are allergic to penicillin.